Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Total Revenue of $25.19 million for fiscal year 2017.
BIOCRYST PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $263.86M +396.9% |
-$88.88M +60.8% |
-$226.54M +8.3% |
-$247.12M -34.3% |
-$184.06M -0.7% |
-$182.81M -67.9% |
| Diluted EPS | $1.21 +381.4% |
-$0.43 +63.6% |
-$1.18 +11.3% |
-$1.33 -29.1% |
-$1.03 +5.5% |
-$1.09 |
| Total Assets | $514.16M +4.8% |
$490.42M -5.1% |
$516.96M -6.0% |
$550.00M -6.5% |
$588.15M +75.7% |
$334.71M +91.0% |
| Cash and Equivalents | $89.74M -14.3% |
$104.71M -5.4% |
$110.64M -63.7% |
$304.77M -39.6% |
$504.39M +85.4% |
$272.13M +138.3% |
| Long-Term Debt | $0.00 -100.0% |
$314.87M +3.8% |
$303.23M +30.9% |
$231.62M +70.2% |
$136.08M +13.7% |
$119.73M |
| Stockholders Equity | -$119.15M +75.0% |
-$475.93M -4.5% |
-$455.53M -54.6% |
-$294.60M -175.4% |
-$106.99M -455.4% |
-$19.26M -150.4% |
| R&D Expense | $166.13M -4.9% |
$174.64M -19.4% |
$216.57M -14.5% |
$253.30M +21.3% |
$208.81M +69.8% |
$122.96M +14.8% |
| Operating Income | $340.99M +13508.9% |
-$2.54M +97.5% |
-$103.71M +30.1% |
-$148.44M +16.5% |
-$177.72M -1.7% |
-$174.76M -75.7% |
| Shares Outstanding | 213.06M +2.2% |
208.54M +1.3% |
205.77M +9.5% |
187.91M +1.9% |
184.35M +4.2% |
176.88M +14.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $8.76M | +12.8% | +182.7% |
| Net Income | September 30, 2025 | $12.90M | +191.9% | +153.7% |
| Diluted EPS | September 30, 2025 | $0.06 | +185.7% | +200.0% |
| Total Assets | September 30, 2025 | $446.42M | -9.1% | -2.4% |
| Cash and Equivalents | September 30, 2025 | $84.08M | -13.2% | -4.5% |
| Long-Term Debt | September 30, 2025 | $194.37M | -38.2% | -19.9% |
| Stockholders Equity | September 30, 2025 | -$387.89M | +17.2% | +8.0% |
| R&D Expense | September 30, 2025 | $44.60M | +8.6% | +2.8% |
| Operating Income | September 30, 2025 | $29.59M | +284.7% | -0.7% |
| Shares Outstanding | September 30, 2025 | 210.52M | +1.6% | +0.3% |
- BIOCRYST PHARMACEUTICALS INC reported Total Revenue of $25.19 million for fiscal year 2017.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -4.4% in Total Revenue compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Net Income of $263.86 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +396.9% in Net Income compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Diluted EPS of $1.21 per share for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +381.4% in Diluted EPS compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Total Assets of $514.16 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +4.8% in Total Assets compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Cash and Equivalents of $89.74 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -14.3% in Cash and Equivalents compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Long-Term Debt of $0.00 for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Stockholders Equity of -$119.15 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +75.0% in Stockholders Equity compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported R&D Expense of $166.13 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -4.9% in R&D Expense compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Operating Income of $340.99 million for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +13508.9% in Operating Income compared to the prior fiscal year.
- BIOCRYST PHARMACEUTICALS INC reported Shares Outstanding of 213.06 million shares for fiscal year 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +2.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: